Indefinite Delivery Contract SPE2DU25D9771

The federal contract IDV award is for an Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, provides a vehicle for the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This contract supports the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide, encompassing a diverse portfolio of pharmaceutical items such as injections, tablets, creams, auto-injectors, and specialty medications. The IDC has a base period of 30 months and three 30-month option periods, providing the DLA with a flexible and efficient means to procure pharmaceutical products to meet the medical supply requirements of the Department of Defense and other government agencies. This contract is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

The original federal contract opportunity was a pre-solicitation for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement. The intent is to establish multiple Prime Vendor Contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, the United States Coast Guard, and the US Naval Fleet. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with the Government planning to make multiple primary supplier awards for separate geographical regions and a single backup supplier award. The estimated total value of the procurement is $30.3 billion.